TLX News: First Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney - 4th Dec 2023, 4:00pm

annb0t

annb0t

Top 20
MELBOURNE, Australia and LIÉGE, Belgium, Dec. 4, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a named patient (early access) program in the Netherlands for its investigational positron emission tomography (PET) imaging agent TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC), the most common and aggressive form of kidney cancer. (PRNewsfoto/Telix Pharmaceuticals Limited)...

>>> Read more: First Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent
 
You must log in or register to reply here.

Similar threads

annb0t
TLX News: Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection - 8th Oct 2024, 7:00am
Replies
0
Views
109
annb0t
annb0t
annb0t
TLX News: Health Canada Approves Label Expansion for Telix’s Illuccix® to Include Patient Selection fo - 4th Oct 2024, 9:00pm
Replies
0
Views
140
annb0t
annb0t
annb0t
TLX News: First Patient Dosed in Phase II 'CA-NINE' Trial of TLX250-CDx for Detection of Recurrent Kidney Canc - 4th Oct 2024, 6:00am
Replies
0
Views
100
annb0t
annb0t
annb0t
TLX News: First Patient Dosed in Phase II ‘CA-NINE’ Trial of TLX250-CDx for Detection of Recurrent K - 3rd Oct 2024, 9:00pm
Replies
0
Views
105
annb0t
annb0t
annb0t
TLX News: First Patient Dosed in U.S. Expanded Access Program for TLX250-CDx, Telix's Breakthrough Kidney Canc - 11th Dec 2023, 10:40pm
Replies
0
Views
164
annb0t
annb0t
Top Bottom